医学
狼牙棒
碘普罗胺
靶病变
气球
冠状动脉疾病
冠状动脉
临床终点
球囊导管
放射科
管腔(解剖学)
紫杉醇
动脉
导管
心脏病学
内科学
血管成形术
再狭窄
支架
临床试验
经皮冠状动脉介入治疗
心肌梗塞
造影剂
化疗
作者
Martin Unverdorben,Franz X. Kleber,Hubertus Heuer,Hans-Reiner Figulla,Christian Vallbracht,Matthias Leschke,Bodo Cremers,Stefan E. Hardt,Michael Buerke,Hanns Ackermann,Michael Boxberger,Ralf Degenhardt,Bruno Scheller
出处
期刊:Eurointervention
[Europa Digital and Publishing]
日期:2013-09-01
卷期号:9 (5): 620-628
被引量:71
摘要
The one-year outcome of lesions in small coronary arteries by using a paclitaxel-iopromide-coated (3 µg/mm²) balloon catheter (DCB) has yielded good six-month angiographic and one-year clinical data. We now report the three-year clinical follow-up.One hundred and twenty patients with >70% stenoses <22 mm in length in small coronary vessels (vessel diameter: 2.25-2.8 mm) were treated with the DCB. The primary endpoint was angiographic in-segment late lumen loss. The secondary endpoints encompassed all other angiographic and clinical data up to three years post intervention. In total 82/120 (68.3%) patients with a vessel diameter of 2.35±0.19 mm were treated with the DCB only, and 32/120 (26.7%) patients required additional bare metal stent (BMS) deployment. Both the 12- and 36-month major adverse cardiac event rates were 5/82 (6.1%) for DCB only and 12/32 (37.5%) for DCB+BMS, primarily due to the need for target lesion revascularisation in 4/82 (4.9%) patients and 9/32 (28.1%) (p<0.001) patients, respectively. Total MACE rate after 36 months was 18/120 (15%; intention-to-treat).Treatment of small vessel coronary artery disease with a paclitaxel-iopromide-coated balloon exhibited good six-month angiographic and one-year clinical data that persisted during the three-year follow-up period. Randomised trials will clarify its role as an alternative to drug-eluting stents in the treatment of small vessel coronary artery disease. (ClinicalTrials.gov Identifier: NCT00404144).
科研通智能强力驱动
Strongly Powered by AbleSci AI